|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest-bearing deposits in other banks | ||||||||||||||||||||
| Total cash and cash equivalents | ||||||||||||||||||||
| Securities-available for sale at fair value, amortized cost of $466,683 and $471,036, respectively | ||||||||||||||||||||
| Loans held for sale, at fair value | ||||||||||||||||||||
| Loans, net of allowance for credit losses of $39,675 and $39,677, respectively | ||||||||||||||||||||
| Restricted stock, at cost | ||||||||||||||||||||
| Corporate premises and equipment, net | ||||||||||||||||||||
| Other real estate owned, net of valuation allowance of $0 and $215, respectively | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other intangible assets, net | ||||||||||||||||||||
| Bank-owned life insurance | ||||||||||||||||||||
| Net deferred tax asset | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Deposits | ||||||||||||||||||||
| Noninterest-bearing demand deposits | ||||||||||||||||||||
| Savings, money market and interest-bearing demand deposits | ||||||||||||||||||||
| Time deposits | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Short-term borrowings | ||||||||||||||||||||
| Long-term borrowings | ||||||||||||||||||||
| Trust preferred capital notes | ||||||||||||||||||||
| FHLB advances | ||||||||||||||||||||
| Subordinated notes | ||||||||||||||||||||
| Other borrowings | ||||||||||||||||||||
| Accrued interest payable | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Equity | ||||||||||||||||||||
| Common stock ($1.00 par value, 8,000,000 shares authorized, 3,250,307 and 3,245,972 shares issued and outstanding, respectively, includes 98,973 and 100,578 of unvested shares, respectively) | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss, net | ||||||||||||||||||||
| Equity attributable to C&F Financial Corporation | ||||||||||||||||||||
| Noncontrolling interest | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
Loading...
